Pipeline Progress: Positive clinical trial results for Denali Therapeutics' drug candidates typically drive the stock price higher, while failures can cause significant drops.

Regulatory Decisions: FDA approvals or rejections of Denali's therapies have a major impact on investor sentiment and therefore the stock's valuation.

Partnerships & Collaborations: Collaboration agreements with larger pharmaceutical companies, especially involving milestone payments, can positively influence the stock price.

Market Sentiment: Overall market conditions, particularly within the biotechnology sector, can influence DNLI's stock performance regardless of company-specific news.

Financial Performance: Revenue, earnings, and cash flow reports affect investor confidence, impacting buying and selling decisions regarding the stock.

Competition: Developments from competitor companies in the neurodegenerative disease space influence market share expectations, potentially affecting DNLI's valuation.

Patent Protection: The strength and scope of Denali's intellectual property portfolio are crucial for future revenue generation and investor confidence, influencing the stock's price.

Economic Conditions: Broad economic factors such as interest rates and inflation can impact investor risk appetite and, in turn, affect the valuation of growth stocks like DNLI.